- Home
- DAVA vs MIST Comparison
DAVA vs MIST Comparison
Compare DAVA & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVA | MIST |
|---|---|---|
| Founded | 2000 | 2003 |
| Country | United Kingdom | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.4M | 176.3M |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DAVA | MIST |
|---|---|---|
| Price | $4.16 | $1.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $13.50 | $8.00 |
| AVG Volume (30 Days) | 216.5K | ★ 2.2M |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,915.14 |
| Revenue Next Year | $4.07 | N/A |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.98 | $1.00 |
| 52 Week High | $20.80 | $3.06 |
Technical Indicators
Market Signals| Indicator | DAVA | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 55.10 |
| Support Level | N/A | $1.84 |
| Resistance Level | $7.04 | $2.01 |
| Average True Range (ATR) | 0.22 | 0.12 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 17.43 | 25.22 |
Price Performance
Historical ComparisonAbout DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).